Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company. In Q3, 2017, Armetheon merged with Espero Pharmaceuticals, Inc to become Espero BioPharma, Inc, a commercial-stage cardiovascular-focused company with 3 marketed products and a potential blockbuster pipeline. [www.esperobio.com]